Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer

[1]  Yongheng Chen,et al.  FGFR-TKI resistance in cancer: current status and perspectives , 2021, Journal of Hematology & Oncology.

[2]  H. Bohnenberger,et al.  Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer , 2020, Cancer medicine.

[3]  Z. Qiu,et al.  Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. , 2020, Oncology letters.

[4]  R. Laskawi,et al.  Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression. , 2020, Oral oncology.

[5]  J. Luo,et al.  A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Neil Vasan,et al.  A view on drug resistance in cancer , 2019, Nature.

[7]  R. Herbst,et al.  SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) , 2019, Journal of Thoracic Oncology.

[8]  J. Molina,et al.  Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.

[9]  K. Tamura,et al.  BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[11]  M. Katoh Fibroblast growth factor receptors as treatment targets in clinical oncology , 2018, Nature Reviews Clinical Oncology.

[12]  Yang Shen,et al.  Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. , 2018, Cancer discovery.

[13]  Kerstin Kutsche,et al.  Activating Mutations in PAK1, Encoding p21-Activated Kinase 1, Cause a Neurodevelopmental Disorder. , 2018, American journal of human genetics.

[14]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[15]  T. Beißbarth,et al.  Comparative proteomics reveals a diagnostic signature for pulmonary head‐and‐neck cancer metastasis , 2018, EMBO molecular medicine.

[16]  S. Moran,et al.  Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells , 2018, Oncotarget.

[17]  C. Chen,et al.  The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.

[18]  Yidan Ren,et al.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance , 2018, Molecular Cancer.

[19]  N. Xu,et al.  ANXA1 affects cell proliferation, invasion and epithelial-mesenchymal transition of oral squamous cell carcinoma. , 2017, Experimental and therapeutic medicine.

[20]  S. Yano,et al.  Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer , 2017, Carcinogenesis.

[21]  Zachary L. Skidmore,et al.  A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer , 2017, Clinical Cancer Research.

[22]  H. Ditzel,et al.  Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer , 2017, Nature Communications.

[23]  M. Berger,et al.  A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers , 2017, Clinical Cancer Research.

[24]  Gabriela Alexe,et al.  Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia , 2017, Cancer cell.

[25]  N. Leighl,et al.  Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine , 2017, Front. Oncol..

[26]  J. Datta,et al.  Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 , 2017, Molecular Cancer Therapeutics.

[27]  Manuel Hidalgo,et al.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Hue Lee,et al.  PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness , 2016, Scientific Reports.

[29]  Huiming Sun,et al.  Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target , 2016, Tumor Biology.

[30]  B. Cho,et al.  Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy , 2016, Oncogenesis.

[31]  M. Mann,et al.  A Proteomics Approach to the Protein Normalization Problem: Selection of Unvarying Proteins for MS-Based Proteomics and Western Blotting. , 2016, Journal of proteome research.

[32]  G. Baldwin,et al.  Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer , 2016, Cancer biology & therapy.

[33]  M. Słabicki,et al.  Elucidation of tonic and activated B-cell receptor signaling in Burkitt’s lymphoma provides insights into regulation of cell survival , 2016, Proceedings of the National Academy of Sciences.

[34]  C. Arteaga,et al.  Is There a Future for AKT Inhibitors in the Treatment of Cancer? , 2016, Clinical Cancer Research.

[35]  M. Kodaira,et al.  Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[36]  Jun Liu,et al.  A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type , 2016, Oncology letters.

[37]  G. Giaccone,et al.  Refining the treatment of NSCLC according to histological and molecular subtypes , 2015, Nature Reviews Clinical Oncology.

[38]  R. Herbst,et al.  Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.

[39]  A. Giuliano,et al.  Critical protein GAPDH and its regulatory mechanisms in cancer cells , 2015, Cancer biology & medicine.

[40]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[41]  H. Popper,et al.  Molecular testing in lung cancer in the era of precision medicine. , 2014, Translational lung cancer research.

[42]  A. Strasser,et al.  Pro-apoptotic BIM is an essential initiator of physiological endothelial cell death independent of regulation by FOXO3 , 2014, Cell Death and Differentiation.

[43]  A. Iafrate,et al.  Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  J. Wolf,et al.  Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer , 2014, Modern Pathology.

[45]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[46]  M. Tenhagen,et al.  p120-catenin in cancer – mechanisms, models and opportunities for intervention , 2013, Journal of Cell Science.

[47]  Mari Mino-Kenudson,et al.  FGFR1 Amplification in Squamous Cell Carcinoma of The Lung , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  T. Zander,et al.  Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer , 2012, Modern Pathology.

[49]  S. MacGrath,et al.  Cortactin in cell migration and cancer at a glance , 2012, Journal of Cell Science.

[50]  D. Coppola,et al.  Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice , 2011, Clinical Cancer Research.

[51]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[52]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[53]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[54]  V. Shidham,et al.  Cell Block Preparation from Cytology Specimen with Predominance of Individually Scattered Cells , 2009, Journal of visualized experiments : JoVE.

[55]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[56]  Viraj J. Jasinghe,et al.  Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion , 2008, Cancer Chemotherapy and Pharmacology.

[57]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[58]  Xin Zhao,et al.  Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  G. Bokoch,et al.  Akt Phosphorylation of Serine 21 on Pak1 Modulates Nck Binding and Cell Migration , 2003, Molecular and Cellular Biology.

[60]  Liuh-Yow Chen,et al.  Daxx Silencing Sensitizes Cells to Multiple Apoptotic Pathways , 2003, Molecular and Cellular Biology.

[61]  D. Reinberg,et al.  ASAP, a Novel Protein Complex Involved in RNA Processing and Apoptosis , 2003, Molecular and Cellular Biology.